<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553172</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0471</org_study_id>
    <nct_id>NCT04553172</nct_id>
  </id_info>
  <brief_title>Vascular Abnormalities and Bleeding Diathesis</brief_title>
  <official_title>Endothelial Dysfunction Leads to Bleeding Diathesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inherited bleeding disorders (IBD) consist of a heterogeneous group of diseases including&#xD;
      coagulation and/or platelets defects and more rarely vascular dysfunctions. A family of four&#xD;
      patients suffering from unexplained excessive bleeding has been followed clinically in France&#xD;
      for many years. Recently, whole exome sequencing (WES) of DNA allowed the identification of a&#xD;
      heterozygous genetic variant which segregated to family members with bleeding diathesis. The&#xD;
      aim of the study was to better characterize the phenotype by studying VWF and platelets in&#xD;
      affected family members ultimately contributing to the pathogenesis of a bleeding diathesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As explained in the brief summary, whole exome sequencing (WES) of DNA was performed in a&#xD;
      family of four patients suffering from unexplained excessive bleeding. It allowed the&#xD;
      identification of a variant which segregated to family members with bleeding diathesis.&#xD;
      Firstly, in vitro, functional analyses were performed in primary human endothelial cells.&#xD;
      Then, in-vivo analysis have to be performed on affected patients.&#xD;
&#xD;
      The four related patients suffering from excessive bleeding have been followed clinically in&#xD;
      France for many years. During the follow-up of three of these affected patients, biological&#xD;
      studies are planned.&#xD;
&#xD;
      Biological assays include:&#xD;
&#xD;
        -  Conventional assessment of primary haemostasis: platelet count, platelet aggregation,&#xD;
           functional and antigen measurement of von Willebrand factor.&#xD;
&#xD;
        -  Specific testing: Von Willebrand factor multimeric profile, immunolabeling of platelets.&#xD;
&#xD;
      Conventional assessment is part of the conventional follow-up of patients with inherited&#xD;
      bleeding disorder. It will not require any additional blood sample. For specific testing and&#xD;
      after informed consent, fresh blood samples of patients will be collected in 1/10 volume of&#xD;
      acid-citrate-dextrose and centrifuged for 10 min at 200 g to obtain Platelet-rich plasma&#xD;
      (PRP) for functional analysis of platelets and Platelet-poor plasma for the multimerization&#xD;
      state of von Willebrand factor. Then, the results will be compared to the in-vitro findings.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Actual">April 1, 2019</completion_date>
  <primary_completion_date type="Actual">November 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>platelet count</measure>
    <time_frame>1 day</time_frame>
    <description>automatic count of platelet</description>
  </primary_outcome>
  <primary_outcome>
    <measure>platelet aggregation</measure>
    <time_frame>1 day</time_frame>
    <description>automated assay using adenosine diphosphate (ADP), arachidonic acid (AA) agonists</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VWF (von Willebrand factor)</measure>
    <time_frame>1 day</time_frame>
    <description>activity/antigen levels measurements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VWF mutimerization status</measure>
    <time_frame>1 day</time_frame>
    <description>multimer distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunostaining of platelets</measure>
    <time_frame>2 to 3 days</time_frame>
    <description>fixed platelet studies coverslips are challenged with a panel of primary antibodies for immunofluorescence staining</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">5</enrollment>
  <condition>Bleeding Diathesis</condition>
  <arm_group>
    <arm_group_label>Affected family members</arm_group_label>
    <description>Affected family members</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Affected PM</arm_group_label>
    <description>Affected PM</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        A specific Family&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        - members of the family&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - patient who refused to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muriel GIANSILY-BLAIZOT</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UH Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mucocutaneous bleeding</keyword>
  <keyword>surgery bleeding outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemorrhagic Disorders</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

